Cancer Immunotherapeutics In the News
City of Hope is now enrolling patients with multiple myeloma whose disease has relapsed, or is treatment-resistant, for a first-of-its kind chimeric antigen receptor (CAR) T cell therapy trial. It will also manufacture CAR T cells in its own laboratories.
City of Hope’s clinical trials program is special because it was built with the same core values as the institution itself: an emphasis on leading-edge medicine, compassionate care, rapid bench-to-bedside research and always putting the patient first.
City of Hope opens recruitment for a phase I/II dose-finding study of novel agent 8-chloro-adenosine in patients with relapsed/refractory acute myeloid leukemia.
City of Hope is now enrolling relapsed/refractory multiple myeloma patients for a first-of-its kind chimeric antigen receptor T cell therapy phase I trial.
City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly impossible-to-treat cancer into a disease that can be corralled into remission.
City of Hope physician-scientists recently opened two clinical trials to investigate a combination of cytokines and immunotherapy that may be able to transform nearly-impossible-to-treat cancer into a disease that can be corralled into remission.
City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma.
City of Hope will showcase ongoing studies and data on chimeric antigen receptor (CAR) T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.
City of Hope will showcase ongoing studies and data on chimeric antigen receptor (CAR) T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research (AACR) annual meeting from March 29 through April 3 in Atlanta.
City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma (CTCL).
Australian lobster fisherman David Thompson traveled 9,000 miles for treatment at City of Hope after being diagnosed with Stage 4 oropharyngeal cancer. Given just six weeks to live, he is thriving more than a year after participating in an immunotherapy clinical trial.
Longtime "Jeopardy" host Alex Trebek was diagnosed with Stage 4 pancreatic cancer. Susanne Gray Warner, M.D., a surgical oncologist at City of Hope, tells us what you need to know regarding the disease, which is the third-leading cause of cancer death.
Stephen J. Forman, M.D., the renowned leader of the Hematologic Malignancies and Stem Cell Transplantation Institute and the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, will receive the 2019 DKMS Mechtild Harf Science Award in honor of his outstanding achievements in cancer immunology, hematology, stem cell transplantation and CAR T cell therapy.
City of Hope has long been renowned for its expertise in treating cancer and diabetes. But specialists here also are tackling lesser-known but equally devastating diseases that may or may not have an oncologic component.
City of Hope has earned its third Lymphoma Specialized Programs of Research Excellence grant from the National Cancer Institute, which provides $12.5 million for research.
An international leader in finding new, innovative treatments for lymphoma patients, City of Hope announced today that it has received its third lymphoma Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI), one of four current NCI-supported lymphoma SPOREs. The grant covers a five-year period and totals $12.5 million.
Vanessa Jonsson, Ph.D., focuses on chimeric antigen receptor (CAR) T cell therapy. Using such tools as computational analysis and mathematical modeling, she examines the complex interactions between the tumor, the patient’s immune system and the therapy to learn how the tumor evades the immune response.
In the three decades since robots first entered the operating room, these increasingly sophisticated machines have helped surgeons perform more than a million procedures, all over the human body.
What's it like to work at the center of a true medical and scientific revolution? It's emotional, often overwhelming. But it’s also a place to witness miracles. Such is the life of the clinical research nurses who staff City of Hope's CAR T cell program.
Meet float rider Cheryl Wiers, a wife and mother of two who battled cancer twice only to have it return. She eventually found prolonged remission thanks to a CAR T Cell therapy offered at City of Hope.
City of Hope clinical and laboratory investigators presented leading-edge research, including new targets in CAR T cell therapy, at the 60th annual ASH meeting in San Diego.
Xiuli Wang, Ph.D., research professor at City of Hope, presented encouraging research on using CAR T cell therapy for central nervous system lymphoma at this year's American Society of Hematology conference.
Physicians and researchers at the 2018 American Society of Hematology conference presented clinical trials for new leukemia and lymphoma treatments, laying the groundwork for innovative therapeutic approaches aimed at improving treatment options and quality of life for patients.
City of Hope physicians and researchers at the American Society of Hematology (ASH) meeting in San Diego presented clinical trials for novel leukemia and lymphoma treatments that could improve outcomes for patients.
CAR T cell therapy is one of the most promising new approaches for treating cancer today. Come spend a day learning more about CAR T cell therapy from City of Hope’s resident experts to better understand what is now at the forefront of oncology treatment.